Generics Overview in the Seven Major Markets

Increasing generics volume uptake will provide much needed cost-savings in the less mature markets of France, Italy, Spain, and Japan, and requires regulators to incorporate effective utilization incentives for key stakeholders. While volume will grow in the US, Germany, and the UK, regulators are increasingly looking to capture value from generics by pushing down price and speeding market access.

US and EU regulators close in on pharmaceutical pay-for-delay deals

The evolving relationship between branded and generics pharmaceutical companies is set to undergo considerable change as regulators in both the US and EU move to restrict 'pay-for-delay' deals in a bid to increase generics cost-savings. As deals that delay the market entry of generics come under increasing scrutiny, the industry may find that its best option is to cease such practices altogether.

Europe Picture Archiving and Communication Systems (PACS) Market: Market Analysis and Opportunity Assessment

GlobalData's "Europe Picture Archiving and Communication Systems (PACS) Market: Market Analysis and Opportunity Assessment" report is an essential source of data and analysis on the Europe PACS market. The report provides market landscape, competitive landscape and market trends information on the Europe PACS market. The report identifies the key trends shaping and driving the dynamism in the Europe PACS market. The report also provides insight on the prevalent competitive landscape and on the emerging players which are expected to bring significant shift in the market standing of the existing leaders. The report also provides valuable insight on the pipeline products within the Europe PACS market.

Claim "10% Discount for Farmavita.Net Members" when purchasing this report!

US Surgical Sutures Market: Surgical Procedures Growth to Drive Demand

GlobalData's "US Surgical Sutures Market: Surgical Procedures Growth to Drive Demand" report is an essential source of data and analysis on the US surgical sutures market with complete coverage by categories. The report provides market landscape, competitive landscape and market trends information on two market categories - absorbable sutures and non absorbable sutures. The report identifies the key trends shaping and driving the dynamism in the US surgical sutures market. The report also provides insight on the prevalent competitive landscape and on the emerging players which are expected to bring significant shift in the market standing of the existing leaders. The report also provides valuable insight on the pipeline products within the US surgical sutures market.

Claim "10% Discount for Farmavita.Net Members" when purchasing this report! 

Minimising Risks
Drug Discovery Best Practises for Chief Scientific Officers

Cannes, France, December 8, 2009

Interview with: Malcolm Weir, Founder & CEO, Heptares Therapeutics

Malcolm Weir, a speaker at the marcus evans Discovery Summit 2010 addresses some of the challenges facing drug discovery Chief Scientific Officers across Europe.

Statistics seem almost stacked against developing a fitting drug for a target disease. Drug discovery is plagued by time consuming and costly processes, with extremely high failure rates. Improving some of the underlying processes strangling and stalling the drug discovery process has thus become a top priority for the industry. A speaker at the marcus evans Discovery Summit 2010 taking place in France, 22-24 March, Malcolm Weir, Founder and CEO of Heptares Therapeutics, shares his thoughts on the solutions to some of the issues troubling drug discovery scientists, the latest trends and building alliances.

ANTI-DIARRHEAL ACTIVITY OF ETHANOLIC EXTRACT OF CALOTROPIS PROCERA R. Br. ROOTS

Calotropis procera R. Br. (Asclepidaceae) is a shrub which widely distribute in the world. The plant is used in the treatment of many disease and disorder both in humans and veterinary application. The present work was undertaken to investigate the anti-diarrhoeal activity of ethanolic extract of root (200 mg/kg BW) of Calotropis procera against castor oil induced diarrhoea in experimental animal and was found to be significant results.

The whole 6 pages article is available for download at Downloads section of Farmavita.Net.

Sanofi-Aventis: CNS franchise takes a knock

Sanofi-Aventis has withdrawn its US and EU applications for its insomnia candidate, eplivanserin. Previously posited by Datamonitor to emerge as a key player in the insomnia market, the drug's discontinuation represents a blow to Sanofi-Aventis' diminishing late-stage CNS pipeline. The company's decision also casts doubt on the future of the serotonergic drug class in the treatment of insomnia.

Sanofi-Aventis: PharmaVitae Profile

This analysis examines the historical and forecast performance for Sanofi-Aventis in the pharmaceutical sector.

Enhancing Sales & Marketing Performance for Oncology Therapeutics

15th-16th March, 2010 - Venue: Brussels, Belgium

This will be the only event looking at „best practice" approaches to selling and marketing high-value cancer drugs, and working in partnership with generalists and specialists such as oncologists, haematologists radiologists and cancer hospitals to provide real value and to improve patient access. One of the goals, will be to improve seamless coordination between all internal stakeholders in strategic, operational and tactical roles at the global, regional and local level

A NEW METHOD FOR THE DEVELOPMENT OF ESCHERICHIA COLI RESISITANT AGAINST ANTIBIOTIC AMPICILLIN

Bacteria are like living paint, covering nearly every surface imaginable and living within a variety of living and nonliving things. An antibiotic is any substance produced by a microorganism, which harms or kills another microorganism. However, antibiotics do not harm viruses. A majority of antibiotic substances are natural products that certain bacteria and fungi produce as a natural defense to send outside their cells.

The whole 9 pages article is available for download at Downloads section of Farmavita.Net.

Discovery Summit 2010

22-24 March 2010

The Majestic Barrière, Cannes

The exclusive Discovery Summit 2010 presents a unique opportunity to examine the challenges and advances in drug discovery. Within the luxurious surroundings of a five star venue, this networking event provides the perfect setting for discussion and knowledge sharing between the most prominent and innovative drug discovery leaders.

The Evolving Pharma M&A Landscape: Emerging trends and predicted post-blockbuster targets

The report identifies the factors responsible for growing pressure on leading pharmaceutical businesses and strategic responses being pursued by the industry. It includes a critical appraisal of mega-mergers triggered by similar factors in the past, and an analysis of the two mega-mergers that have been announced since the beginning of 2009.

Development and evaluation of controlled release mucoadhesive tablets of Tramadol Hydrochloride

The present investigation concerns the development of mucoadhesive tablets of Tramadol Hydrochloride which were designed to prolong the gastric residence time after oral administration. Tablets of Tramadol Hydrochloride were formulated using four mucoadhesive polymers namely guar gum, xanthan gum, HPMC K15M and HPMC K100M and carried out studies for its evaluation parameters. Formulations F15 and F16 containing polymers of Xanthan gum, HPMC K100M and HPMC K15M were established to be the optimum formulation since it shows optimum bioadhesive force, swelling index & desired evaluation standards. Further investigations are needed to confirm the in vivo efficiency, long term stability studies are needed to stabilize the controlled released formulations.

The whole 8 pages article is available for download at Downloads section of Farmavita.Net.

Boston Scientific, DePuy, Hospira and Philips Healthcare meet to share best practice sales and marketing tips with the European medical device industry

London, 14 December 2009

Over 20 senior level speakers will gather at MDDexec's European Sales & Marketing Summit, 17-18 March 2010, London.

Representatives from leading corporates such as Boston Scientific, DePuy, Hospira and Philips Healthcare are set to gather in March to share best practice alongside more than fifteen fellow executives for two days of focused debate and networking at the European Sales and Marketing Summit, a two-day business conference organised by MDDexec on 17th and 18th March 2010, in London.

RECENT APPROACHES IN MICROSPHERES: A NOVEL DRUG DELIVERY SYSTEM

Microsphere technology has been studied extensively for the sustained delivery of therapeutic agents. Microspheres can be manufactured from various natural and synthetic materials. Glass microspheres, polymer microspheres and ceramic microspheres are commercially available. Recent researches are confined to the discovery of active microspheres in the treatment of cancers. The present paper review the recent approaches in microspheres technology, a novel drug delivers system.

The whole 6 pages article is available for download at Downloads section of Farmavita.Net.

ESTIMATION OF MICROBIAL LIMITS IN OILS

Oil is an important source of fat and is important in human diet. The microbial limit tests are designed to perform the qualitative and quantitative estimations of specific viable microorganisms present in pharmaceutical substances or in the samples. The present paper deals with the various procedures in estimation of microbial limits in oils.

The whole 4 pages article is available for download at Downloads section of Farmavita.Net.

RECENT ADVANCES IN DIFFERENT ASPECTS OF TABLET COATING

Coated tablets are defined as tablets covered with one or more layers of mixture of various substances such as natural or synthetic resins ,gums ,inactive and insoluble filler, sugar, plasticizer, polyhydric alcohol, waxes, authorized colouring material and some times flavoring material. Coating may also contain active ingredient. Substances used for coating are usually applied as solution or suspension under conditions where vehicle evaporates. The present paper reviews recent advances in different aspects of tablet coating.

The whole 16 pages article is available for download at Downloads section of Farmavita.Net.

Colorectal Cancer - Growing trend towards personalized medicine

CRC incidence will be over 490,000 cases by 2018 in the seven major markets. This large patient base will translate into a high commercial potential for the development of novel, more effective therapies. Currently, there are 77 agents in development for CRC, 4 of which are in late-phase development. Collectively, they are forecast to achieve sales of $1,398m by 2018.